Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 130.55% from the company’s previous close.

A number of other research firms have also recently weighed in on TSHA. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Raymond James Financial started coverage on Taysha Gene Therapies in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 target price on the stock. JMP Securities set a $8.00 price target on Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Citizens Jmp lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA traded up $0.32 on Tuesday, hitting $5.21. 2,405,941 shares of the company traded hands, compared to its average volume of 2,339,102. The business’s 50 day moving average price is $4.91 and its 200-day moving average price is $3.81. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -15.79 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.78% of the stock is owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of large investors have recently added to or reduced their stakes in the business. B Group Inc. increased its stake in shares of Taysha Gene Therapies by 43.4% during the second quarter. B Group Inc. now owns 1,800,556 shares of the company’s stock valued at $4,159,000 after buying an additional 545,000 shares during the period. Rice Hall James & Associates LLC purchased a new stake in Taysha Gene Therapies in the third quarter worth about $1,890,000. Affinity Asset Advisors LLC bought a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $462,000. Jefferies Financial Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 4,105.3% during the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after purchasing an additional 10,068,479 shares during the last quarter. Finally, Octagon Capital Advisors LP boosted its position in shares of Taysha Gene Therapies by 2.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company’s stock worth $14,873,000 after purchasing an additional 250,000 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.